Publication | Closed Access

HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation

Molecular PharmacologyHdac6 InhibitionCardiomyopathyDoxorubicin-induced Acute DamageMedicineCardiovascular PharmacologyCell DeathPharmacotherapyCellular BiochemistryCardiovascular ToxicityPharmacologyCell BiologyCell SignalingCellular Physiologyα-Tubulin Acetylation